logoTry Persana

Arsenal Biosciences, Inc. - Company Overview, Founder, CEO, Funding & Investment Details

Complete information about Arsenal Biosciences, Inc. including founder details, CEO information, total funding raised, headquarters location, team size, and recent investment rounds.

Arsenal Biosciences, Inc. company logo

Clinical stage programmable cell therapy company focused on cancer treatments.

Arsenal Biosciences, Inc. focuses on developing programmable cell therapies to defeat cancer, utilizing advanced technologies such as CRISPR and machine learning.

HeadquartersSouth San Francisco, United States
Team size201-500
Founded2019

What is Arsenal Biosciences, Inc.? - Company Overview & Details

Arsenal Biosciences, Inc. is Arsenal Biosciences, Inc. focuses on developing programmable cell therapies to defeat cancer, utilizing advanced technologies such as CRISPR and machine learning. Founded in 2019, the company is headquartered in South San Francisco, United States.

Who Founded Arsenal Biosciences, Inc.?

Arsenal Biosciences, Inc. was founded by Ken Drazan.

Who are the Key Executives at Arsenal Biosciences, Inc.? - Leadership Team

Arsenal Biosciences, Inc. is led by experienced executives in key positions:

Arsenal Biosciences, Inc. Company Details & Key Information

Where is Arsenal Biosciences, Inc. located?

Arsenal Biosciences, Inc. is headquartered in South San Francisco, United States.

How many employees does Arsenal Biosciences, Inc. have?

Arsenal Biosciences, Inc. has 201-500 employees.

When was Arsenal Biosciences, Inc. founded?

Arsenal Biosciences, Inc. was founded in 2019.

How much funding has Arsenal Biosciences, Inc. raised?

Arsenal Biosciences, Inc. has raised $305 Million across 5 funding rounds. The most recent funding was completed on 2024-09-05.

Funding Overview

Arsenal Biosciences, Inc. has raised significant capital through multiple funding rounds, positioning itself as a leader in innovative cancer therapies.

$305 Million
Total Funding Raised
5
Funding Rounds
2024-09-05
Latest Round

Arsenal Biosciences, Inc. Funding History

Series C
2024-09-05
$325 Million
Series B
2022-09-06
$220 Million
Series A
2019-07-01
$85 Million

Who are the key investors in Arsenal Biosciences, Inc.?

Arsenal Biosciences, Inc. is backed by 3 key investors including Bristol-Myers Squibb, SoftBank Vision Fund, Sean Parker Institute for Cancer Immunotherapy. These investors focus on Pharmaceuticals, Biotechnology, Technology sectors.

Arsenal Biosciences, Inc. Investor Overview

3
Key Investors
6
Focus Areas
0
Notable Investments

Complete List of Arsenal Biosciences, Inc. Investors

Bristol-Myers Squibb

A leading global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases.

Investment Focus
Pharmaceuticals
Biotechnology

SoftBank Vision Fund

A global investment fund focused on technology, particularly those related to AI and advanced technology companies.

Investment Focus
Technology
AI
Biotechnology

Sean Parker Institute for Cancer Immunotherapy

A research institute that promotes collaboration between top researchers in cancer immunotherapy.

Investment Focus
Cancer Research
Immunotherapy

What sectors do Arsenal Biosciences, Inc. investors focus on?

The investors backing Arsenal Biosciences, Inc. primarily focus on Pharmaceuticals, Biotechnology, Technology, AI, Cancer Research, Immunotherapy sectors.

Pharmaceuticals
Biotechnology
Technology
AI
Cancer Research
Immunotherapy

Featured Investor: Bristol-Myers Squibb

Bristol-Myers Squibb

A leading global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases.

Notable Investments:

What are Arsenal Biosciences, Inc.'s future plans?

Arsenal Biosciences, Inc. ArsenalBio aims to scale up manufacturing capabilities and expand clinical trials for novel therapies.

Arsenal Biosciences, Inc. Strategic Outlook

Strategic Focus
Defined
2
Key Challenges
2
Growth Opportunities

What challenges does Arsenal Biosciences, Inc. face?

Arsenal Biosciences, Inc. has identified 2 key challenges that need to be addressed for continued growth and success.

Key Challenges for Arsenal Biosciences, Inc.

1

Expanding manufacturing capabilities

2

Addressing solid tumor complexities

What opportunities does Arsenal Biosciences, Inc. have?

Arsenal Biosciences, Inc. has identified 2 key opportunities for growth and market expansion.

Growth Opportunities for Arsenal Biosciences, Inc.

1

Developing next-generation T-cell therapies

2

Forming strategic partnerships with industry leaders

Arsenal Biosciences, Inc. Strategic Position Summary

Key Focus Areas

Arsenal Biosciences, Inc. is addressing 2 strategic challenges to strengthen its market position.

Growth Potential

The company has identified 2 key opportunities for expansion and growth.

What are the latest news about Arsenal Biosciences, Inc.?

Arsenal Biosciences, Inc. has 2 recent news updates covering key business developments and market activities.

Arsenal Biosciences, Inc. News Overview

2
Recent Articles
Active
Media Coverage
2024-09-16
Latest Update

What is Arsenal Biosciences, Inc. in the news for?

Arsenal Biosciences, Inc. is currently featured in news for Arsenal Biosciences, Inc. hired Nate Hardy as Chief Financial Officer on Oct 7th '24. and other significant business developments.

Recent News Articles About Arsenal Biosciences, Inc.

Article 1
2024-09-16

Arsenal Biosciences, Inc. hired Nate Hardy as Chief Financial Officer on Oct 7th '24.

Nate Hardy will join Arsenal Biosciences, Inc. as Chief Financial Officer, effective October 7, 2024.

bakersfield.com
Read News
Article 2
2024-09-05

Arsenal Biosciences, Inc. bags $325 million for CRISPR-engineered cell therapies.

ArsenalBio secures $325 million in a Series C round to develop T cell therapies targeting solid tumors.

biopharma-reporter.com
Read News

Arsenal Biosciences, Inc. FAQ - Frequently Asked Questions About Founder, CEO, Funding & Company Details

Find answers to the most common questions about Arsenal Biosciences, Inc. including information about founders, CEO, funding history, investors, headquarters location, and company details. 15 frequently asked questions covering key information about the company.

Arsenal Biosciences, Inc. Questions & Answers - Company Information

Q1

What is Arsenal Biosciences, Inc.?

Arsenal Biosciences, Inc. focuses on developing programmable cell therapies to defeat cancer, utilizing advanced technologies such as CRISPR and machine learning.

Q2

Who founded Arsenal Biosciences, Inc.?

Arsenal Biosciences, Inc. was founded by Ken Drazan.

Q3

How much funding has Arsenal Biosciences, Inc. raised?

Arsenal Biosciences, Inc. has raised a total of $$305 Million across 5 funding rounds. The most recent funding was completed on 2024-09-05.

Q4

Who are the investors in Arsenal Biosciences, Inc.?

Arsenal Biosciences, Inc.'s key investors include Bristol-Myers Squibb, SoftBank Vision Fund, Sean Parker Institute for Cancer Immunotherapy.

Q5

Where is Arsenal Biosciences, Inc. headquartered?

Arsenal Biosciences, Inc. is headquartered in South San Francisco, United States.

Q6

When was Arsenal Biosciences, Inc. founded?

Arsenal Biosciences, Inc. was founded in 2019.

Q7

How many employees does Arsenal Biosciences, Inc. have?

Arsenal Biosciences, Inc. has 201-500 employees.

Q8

What was Arsenal Biosciences, Inc.'s latest funding round?

Arsenal Biosciences, Inc.'s latest funding round was a Series C round of $$325 Million completed on 2024-09-05.

Q9

What does the company do?

Arsenal Biosciences, Inc. focuses on developing programmable cell therapies to defeat cancer, utilizing advanced technologies such as CRISPR and machine learning.

Q10

How much funding?

$305 Million

Q11

Latest funding date?

2024-09-05

Q12

Who are the investors?

Bristol-Myers Squibb SoftBank Vision Fund Sean Parker Institute for Cancer Immunotherapy

Q13

What are the challenges?

Expanding manufacturing capabilities Addressing solid tumor complexities

Q14

What are the opportunities?

Developing next-generation T-cell therapies Forming strategic partnerships with industry leaders

Q15

Latest news?

Nate Hardy will join Arsenal Biosciences, Inc. as Chief Financial Officer, effective October 7, 2024. ArsenalBio secures $325 million in a Series C round to develop T cell therapies targeting solid tumors.

More Information About Arsenal Biosciences, Inc.

For additional details about Arsenal Biosciences, Inc., including the latest news, funding updates, and company developments, explore our comprehensive company database. Find information about startup funding, company valuations, executive leadership, and business intelligence data.